Biogen's Litifilimab Shows Durable CLE Results at 52 Weeks

Biogen Inc. released 52-week data from the Phase 2 portion of its ongoing AMETHYST Phase 2/3 trial of litifilimab, a drug being developed for cutaneous lupus erythematosus, a chronic autoimmune condition primarily affecting the skin. The findings, presented Thursday at the European Academy of Dermatology and Venereology Congress in Vienna, represent the longest dataset yet published for the experimental therapy in this indication.

Participants who received litifilimab during the double-blind, placebo-controlled phase of the study continued to show measurable reductions in skin disease activity through the full 52-week observation window. The sustained response suggests the drug's efficacy does not meaningfully erode over time, an important consideration for a condition that typically requires long-term disease management.

Read more Taysha Gene Therapies Issues Equity Grants to Four New Hires →

Among the notable findings, patients who had initially received a placebo and then crossed over to litifilimab at the 24-week mark began responding as early as four weeks after switching. That rapid onset of effect could be clinically meaningful for dermatologists and patients seeking timely relief from a disease that can cause significant disfigurement and psychological burden.

Biogen is positioning litifilimab as a potential first-in-class therapy for CLE, a market with limited approved treatment options. The Cambridge, Massachusetts-based company has not yet announced a timeline for regulatory submissions based on these Phase 2 results, which will inform the larger Phase 3 portion of the AMETHYST program still underway.

Continue reading at GlobeNewswire - Industry News on Financial Services